• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, March 30, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

The Bill & Melinda Gates Foundation funds Instituto Gulbenkian de Ciencia scientists

Bioengineer.org by Bioengineer.org
January 25, 2018
in Headlines, Health, Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

The research group led by Miguel Soares at Instituto Gulbenkian de Ciência (IGC; Portugal) was specifically selected by The Bill and Melinda Gates Foundation to help finding a vaccine against malaria. For the next two years, the research team will be awarded 400 000 USD to assess if a specific sugar molecule expressed by Plasmodium, the causative agent of malaria, should be included as part of a novel malaria vaccine. This is the second time that the Miguel Soares and his team are recognized by the Gates Foundation.

More than 200 million people suffered from malaria worldwide, last year alone. The Gates Foundation sets a clear goal: "a world free of malaria by 2020". To achieve this, the foundation runs highly competitive initiatives where scientists propose bold and pioneering ways to find a vaccine against malaria. Less than two years ago, Miguel Soares team discovered that a specific sugar molecule – the α-gal glycan – expressed by bacterial components in the human gut microbiota can trigger a natural defense mechanism that is highly protective against malaria transmission. This research work was then published in the prestigious scientific journal Cell. Now, The Bill and Melinda Gates Foundation invited Miguel Soares to use these discoveries to help developing a vaccine against malaria.

An important outcome of this research project is "to guide the Foundation's decision on future investment on the use of glycans in candidate malaria vaccine that block Plasmodium transmission", says Miguel Soares. "Our project will assess if this sugar molecule can be used as a target for a malaria vaccine. Using the platform assays of the Bill and Melinda Gates Foundation, we will assess whether specific antibodies against α-gal can prevent malaria transmission", explains Miguel Soares.

This project will be developed in collaboration with Prof. Henrique Silveira at the Instituto de Higiene e Medicina Tropical (IHMT; Portugal) and the Malaria Vaccine Initiative (MVI).

###

Media Contact

Ines Domingues
[email protected]
351-214-464-642
@IGCiencia

http://www.igc.gulbenkian.pt

Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Chemotherapy Drug Inflicts RNA Damage in Stressed Cells

March 30, 2026

HKUMed Unveils Broader Potential of Fatty Liver Medication in Liver Cancer Prevention and Treatment

March 30, 2026

Promising GPVI Inhibitor Advances Toward Clinical Development for Stroke Treatment

March 30, 2026

How Bacteria Outsmart the Immune System: Unveiling Their Two-Pronged Defense Strategy

March 30, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1005 shares
    Share 397 Tweet 248
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Advancements in EV Battery Technology to Surpass Climate Change-Induced Degradation

    45 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Chemotherapy Drug Inflicts RNA Damage in Stressed Cells

HKUMed Unveils Broader Potential of Fatty Liver Medication in Liver Cancer Prevention and Treatment

Promising GPVI Inhibitor Advances Toward Clinical Development for Stroke Treatment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.